vs
H&R BLOCK INC（HRB）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是H&R BLOCK INC的1.1倍（$219.9M vs $198.9M），Orthofix Medical Inc.净利率更高（-1.0% vs -121.8%，领先120.8%），H&R BLOCK INC同比增速更快（11.1% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-649.5M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -69.8%）
H&R Block是美国知名税务服务企业，1955年由亨利·布洛克与理查德·布洛克兄弟在密苏里州堪萨斯城创立，目前业务范围覆盖美国、加拿大、澳大利亚三地，为个人及企业客户提供专业的税务申报、咨询等相关服务，在行业内拥有较高知名度。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
HRB vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.1倍
$198.9M
营收增速更快
HRB
高出9.1%
2.0%
净利率更高
OFIX
高出120.8%
-121.8%
自由现金流更多
OFIX
多$666.3M
$-649.5M
两年增速更快
OFIX
近两年复合增速
-69.8%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $198.9M | $219.9M |
| 净利润 | $-242.2M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | -160.5% | 0.2% |
| 净利率 | -121.8% | -1.0% |
| 营收同比 | 11.1% | 2.0% |
| 净利润同比 | 0.5% | 92.4% |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HRBOFIX
| Q4 25 | $198.9M | $219.9M | ||
| Q3 25 | $203.6M | $205.6M | ||
| Q2 25 | $1.1B | $203.1M | ||
| Q1 25 | $2.3B | $193.6M | ||
| Q4 24 | $179.1M | $215.7M | ||
| Q3 24 | $193.8M | $196.6M | ||
| Q2 24 | $1.1B | $198.6M | ||
| Q1 24 | $2.2B | $188.6M |
净利润HRBOFIX
| Q4 25 | $-242.2M | $-2.2M | ||
| Q3 25 | $-165.8M | $-22.8M | ||
| Q2 25 | $299.4M | $-14.1M | ||
| Q1 25 | $722.3M | $-53.1M | ||
| Q4 24 | $-243.4M | $-29.1M | ||
| Q3 24 | $-172.6M | $-27.4M | ||
| Q2 24 | $257.8M | $-33.4M | ||
| Q1 24 | $690.7M | $-36.0M |
毛利率HRBOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | 57.4% | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | 57.6% | 67.5% |
营业利润率HRBOFIX
| Q4 25 | -160.5% | 0.2% | ||
| Q3 25 | -106.3% | -8.3% | ||
| Q2 25 | 33.1% | -7.9% | ||
| Q1 25 | 42.1% | -25.2% | ||
| Q4 24 | -174.4% | -5.3% | ||
| Q3 24 | -119.8% | -9.6% | ||
| Q2 24 | 33.0% | -12.5% | ||
| Q1 24 | 41.5% | -15.6% |
净利率HRBOFIX
| Q4 25 | -121.8% | -1.0% | ||
| Q3 25 | -81.5% | -11.1% | ||
| Q2 25 | 27.0% | -6.9% | ||
| Q1 25 | 31.7% | -27.4% | ||
| Q4 24 | -135.9% | -13.5% | ||
| Q3 24 | -89.0% | -13.9% | ||
| Q2 24 | 24.3% | -16.8% | ||
| Q1 24 | 31.6% | -19.1% |
每股收益（稀释后）HRBOFIX
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.57 | ||
| Q2 25 | — | $-0.36 | ||
| Q1 25 | $5.31 | $-1.35 | ||
| Q4 24 | — | $-0.76 | ||
| Q3 24 | — | $-0.71 | ||
| Q2 24 | — | $-0.88 | ||
| Q1 24 | $4.86 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $349.2M | $82.0M |
| 总债务越低越好 | $2.4B | — |
| 股东权益账面价值 | $-823.1M | $450.0M |
| 总资产 | $2.9B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HRBOFIX
| Q4 25 | $349.2M | $82.0M | ||
| Q3 25 | $376.4M | $62.9M | ||
| Q2 25 | $983.3M | $65.6M | ||
| Q1 25 | $772.9M | $58.0M | ||
| Q4 24 | $320.1M | $83.2M | ||
| Q3 24 | $415.9M | $30.1M | ||
| Q2 24 | $1.1B | $26.4M | ||
| Q1 24 | $794.6M | $27.0M |
总债务HRBOFIX
| Q4 25 | $2.4B | — | ||
| Q3 25 | $1.7B | $157.2M | ||
| Q2 25 | $1.1B | $157.0M | ||
| Q1 25 | $1.1B | $156.9M | ||
| Q4 24 | $1.9B | $157.0M | ||
| Q3 24 | $1.5B | $118.5M | ||
| Q2 24 | $1.5B | $118.0M | ||
| Q1 24 | $1.5B | $118.2M |
股东权益HRBOFIX
| Q4 25 | $-823.1M | $450.0M | ||
| Q3 25 | $-550.9M | $442.5M | ||
| Q2 25 | $88.9M | $458.3M | ||
| Q1 25 | $-192.8M | $458.3M | ||
| Q4 24 | $-872.5M | $503.1M | ||
| Q3 24 | $-368.1M | $525.9M | ||
| Q2 24 | $90.6M | $546.0M | ||
| Q1 24 | $-129.8M | $570.3M |
总资产HRBOFIX
| Q4 25 | $2.9B | $850.6M | ||
| Q3 25 | $2.6B | $832.6M | ||
| Q2 25 | $3.3B | $837.2M | ||
| Q1 25 | $3.2B | $823.1M | ||
| Q4 24 | $2.7B | $893.3M | ||
| Q3 24 | $2.5B | $867.9M | ||
| Q2 24 | $3.2B | $882.0M | ||
| Q1 24 | $3.2B | $906.0M |
负债/权益比HRBOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | 12.86× | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | 16.46× | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-614.0M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $-649.5M | $16.8M |
| 自由现金流率自由现金流/营收 | -326.6% | 7.6% |
| 资本支出强度资本支出/营收 | 17.9% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $524.1M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流HRBOFIX
| Q4 25 | $-614.0M | $27.7M | ||
| Q3 25 | $-356.8M | $12.4M | ||
| Q2 25 | $251.6M | $11.6M | ||
| Q1 25 | $1.3B | $-18.4M | ||
| Q4 24 | $-567.1M | $23.7M | ||
| Q3 24 | $-328.6M | $11.7M | ||
| Q2 24 | $300.6M | $9.0M | ||
| Q1 24 | $1.4B | $-18.6M |
自由现金流HRBOFIX
| Q4 25 | $-649.5M | $16.8M | ||
| Q3 25 | $-370.0M | $2.5M | ||
| Q2 25 | $241.3M | $4.5M | ||
| Q1 25 | $1.3B | $-25.1M | ||
| Q4 24 | $-597.4M | $15.2M | ||
| Q3 24 | $-347.3M | $6.3M | ||
| Q2 24 | $290.7M | $-360.0K | ||
| Q1 24 | $1.3B | $-29.1M |
自由现金流率HRBOFIX
| Q4 25 | -326.6% | 7.6% | ||
| Q3 25 | -181.8% | 1.2% | ||
| Q2 25 | 21.7% | 2.2% | ||
| Q1 25 | 57.2% | -13.0% | ||
| Q4 24 | -333.6% | 7.0% | ||
| Q3 24 | -179.2% | 3.2% | ||
| Q2 24 | 27.4% | -0.2% | ||
| Q1 24 | 61.4% | -15.4% |
资本支出强度HRBOFIX
| Q4 25 | 17.9% | 4.9% | ||
| Q3 25 | 6.5% | 4.8% | ||
| Q2 25 | 0.9% | 3.5% | ||
| Q1 25 | 1.0% | 3.5% | ||
| Q4 24 | 17.0% | 4.0% | ||
| Q3 24 | 9.7% | 2.7% | ||
| Q2 24 | 0.9% | 4.7% | ||
| Q1 24 | 1.0% | 5.6% |
现金转化率HRBOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.84× | — | ||
| Q1 25 | 1.83× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.17× | — | ||
| Q1 24 | 1.97× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HRB
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
